Novo Nordisk Reports High-Dose Wegovy Achieves Nearly 28% Weight Loss in Some Patients

Novo Nordisk (NVO) presented new data showing the high-dose version of its obesity drug Wegovy led to an average weight loss of nearly 27.7% for some patients after 72 weeks, positioning it as a stronger competitor against Eli Lilly's Zepbound.

By Annika Kim Constantino · CNBC · May 12, 2026, 14:00 UTC

Tickers: $LLY $NVO

Topics: clinical trials obesity drugs Wegovy Zepbound

Read the full article at CNBC

More Health news

Eli Lilly Shares Rise Following Positive Clinical Trial Results for Retatrutide and Foundayo Motley Fool · November 12, 2026, 17:15 UTC
Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC